What is the approximate latest price of 2025 Mifafa peptide injection?

Mifamurtide injection (Mifamurtide) is an innovative drug for the treatment of osteosarcoma. It is mainly suitable for children and young adults with high-risk, recurrent or metastatic osteosarcoma. Miavamutide helps improve the survival rate of patients by enhancing the body's immune response and activating macrophages and other immune cells, thereby promoting the attack on tumor cells.

In clinical applications, mivamutide is usually used as an auxiliary means, combined with other anti-tumor treatments, aiming to improve the overall effect of treatment. This drug has been verified through rigorous clinical trials, and its efficacy has significantly improved the disease-free survival of osteosarcoma patients to a certain extent. However, since the drug is not yet on the market in China, it is not currently covered by medical insurance, and patients need to bear all costs when receiving treatment.

In the international market, mivamutide has been approved and launched. The common specification is 4mg per box and the price is about more than 30,000 yuan. The actual price of this drug may vary due to exchange rate fluctuations. This may bring greater financial pressure to many families, especially those with limited economic conditions. When faced with a major disease like cancer, high drug costs often become an unbearable burden for patients and their families.

Although mivamutide has shown good promise in the treatment of osteosarcoma, domestic patients are still unable to enjoy this advanced therapy. With the gradual relaxation of my country's anti-tumor drug approval policies and the intensification of market competition, mivamutide is expected to obtain marketing approval in the Chinese market in the future. This will provide new treatment options for more patients who need the drug and potentially reduce their financial burden.

Reference materials:https://en.wikipedia.org/wiki/Mifamurtide